PT-141

At a glance

---

What is PT-141?

PT-141 (bremelanotide) is a synthetic cyclic peptide — a ring-shaped chain of 7 amino acids — that activates melanocortin receptors in the brain to increase sexual desire. It's sold under the brand name Vyleesi and is the only FDA-approved peptide drug specifically developed for women's sexual health.^[12]

The compound has an unusual origin story. In the 1980s, researchers at the University of Arizona were developing analogs of alpha-MSH (melanocyte-stimulating hormone) as sunless tanning agents. They created Melanotan II (MT-II), and during testing, a researcher accidentally self-administered a double dose — and experienced an 8-hour erection. The sexual arousal effects of melanocortin agonists were discovered by accident.

Palatin Technologies picked up the research, stopped developing Melanotan II in 2000 (due to severe nausea), and synthesized bremelanotide — a likely active metabolite of MT-II with a slightly different chemical structure (a hydroxyl group where MT-II has an amide). Bremelanotide retained the sexual function effects while being better tolerated.

After a long development journey that included an FDA clinical hold on the intranasal formulation (blood pressure concerns in 2007), reformulation as a subcutaneous injection, multiple corporate partnerships, and two large Phase 3 trials, bremelanotide was approved in June 2019 as Vyleesi for HSDD in premenopausal women.

---

How it works

In plain terms, PT-141 activates a specific receptor in the brain's desire circuit. Unlike Viagra or Cialis — which work on blood vessels to enable erections — PT-141 works centrally to generate desire itself. This is a fundamentally different approach.^[9]

Detailed mechanism (for advanced readers)

Bremelanotide is a non-selective melanocortin receptor agonist with the following potency order: MC1R > MC4R > MC3R > MC5R > MC2R.^[11]

The sexual function effects are primarily mediated through MC4R (melanocortin-4 receptor) in the medial preoptic area (mPOA) of the hypothalamus:

• MC4R activation → dopamine release: Activates presynaptic MC4Rs on neurons in the mPOA, increasing release of dopamine — the excitatory neurotransmitter that drives sexual desire.
• Neural circuit modulation: Modulates functional connectivity between the amygdala and insula during erotic stimuli, enhancing sexual processing in the brain.
• Desire-specific effect: Preclinical behavioral studies show bremelanotide selectively increases solicitation behaviors (desire) in female rats without altering pacing or lordosis (receptivity) — indicating a targeted effect on desire rather than a general arousal response.^[10]

Other receptor effects:

• MC1R activation (skin): Causes the focal hyperpigmentation (skin darkening) seen as a side effect. This is the same receptor responsible for melanin production in tanning.
• MC3R activation (CNS): May contribute to appetite suppression and the GI side effects (nausea).

How it differs from other sexual function treatments:

• vs. PDE5 inhibitors (Viagra/Cialis): Act peripherally on blood vessel smooth muscle. Require pre-existing arousal. Do not address desire.
• vs. Flibanserin (Addyi): A serotonin receptor modulator taken daily as an oral pill with an alcohol restriction. Different receptor system (5-HT1A agonist, 5-HT2A antagonist) targeting serotonin rather than dopamine.
• vs. Melanotan II: Bremelanotide is a metabolite/derivative of MT-II. MT-II has stronger tanning effects and is not FDA-approved for any indication. MT-II is prohibited by WADA; bremelanotide is not.

---

What the research says

PT-141 has a substantially more robust evidence base than most peptides discussed in wellness communities. It completed the full FDA development pathway — including two identical Phase 3 RCTs, which is the gold standard for drug approval.^[1]

Key clinical trials

The RECONNECT trials are the cornerstone evidence. They used validated coprimary endpoints — the Female Sexual Function Index desire domain (FSFI-D) and the Female Sexual Distress Scale (FSDS-DAO Item 13) — and both studies independently met both endpoints.^[1]

Early evidence in men

PT-141 was initially studied for erectile dysfunction in men before the program pivoted to women's HSDD. Small Phase 1/2 studies showed that PT-141 produced statistically significant erectile responses, and combination with low-dose sildenafil was more effective than sildenafil alone.^[5][6]

No Phase 3 trial in men has been completed. The largest study that claimed positive results (Safarinejad 2008, n=342) received an expression of concern from the journal in 2023, and a related paper by the same author was retracted. We have excluded this study from our evidence assessment.

Palatin Technologies has initiated a Phase 2 study of bremelanotide combined with PDE5 inhibitors for ED in PDE5i non-responders, with results expected in the near future.

Emerging research

Beyond sexual dysfunction, bremelanotide's melanocortin receptor activation has opened two other research avenues:

• Obesity: Palatin Technologies completed a Phase 2 trial combining bremelanotide with tirzepatide (the GLP-1/GIP agonist). The combination group showed 4.4% weight reduction vs 1.6% placebo — leveraging MC4R's known role in appetite regulation. This is at an early stage.
• Diabetic nephropathy: The BREAKOUT Phase 2b study in type 2 diabetic kidney disease showed 71% of patients achieved >30% reduction in urine protein/creatinine ratio. Preliminary but notable.

Neither of these indications is approved or advanced enough to make clinical recommendations.

---

What the evidence shows

People come to PT-141 with specific questions. Here's what the published research actually tells us:

---

Safety & side effects

What clinical trials show

The safety profile of bremelanotide is well-characterized thanks to the large development program — approximately 3,500 subjects across 43 completed studies.^[7]

Most common adverse events (Phase 3 trials):

No deaths occurred in the clinical development program. Serious adverse events were rare.

Nausea — the main barrier

Nausea is the defining tolerability challenge. It's caused by melanocortin receptor activation in the GI tract and brainstem — it's inherent to the mechanism, not an impurity or formulation issue.

• Timing: Typically starts within the first hour after injection
• Duration: Usually resolves within 2 hours
• Trajectory: Improves for most women after the first dose
• Management: 13% of trial participants required anti-emetic therapy
• Discontinuation: 8% stopped treatment because of nausea — the most common reason for dropout

Blood pressure

Bremelanotide causes small, transient increases in blood pressure — typically +2.4-3.2 mmHg systolic, peaking at 0-4 hours post-dose, resolving within 12 hours. Heart rate may decrease by up to 5 bpm.^[8]

This is why the drug is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease.

Skin hyperpigmentation

Drug interaction: naltrexone

Bremelanotide slows gastric emptying, which significantly reduces oral naltrexone absorption (Cmax decreased ~60%, AUC decreased ~40%). Patients using naltrexone-containing products for alcohol or opioid addiction should avoid bremelanotide.^[14]

Contraindications and precautions

Contraindications:

• Uncontrolled hypertension
• Known cardiovascular disease

Precautions:

• Cardiovascular risk should be assessed before initiating and periodically during treatment
• Not recommended in patients at high cardiovascular risk
• No more than 1 dose per 24 hours, no more than 8 doses per month
• Discontinue after 8 weeks if no improvement
• May reduce absorption of other oral medications due to slowed gastric emptying

Not studied in:

• Postmenopausal women (Phase 3 trials enrolled only premenopausal women)
• Pregnancy and breastfeeding

---

How people use it

FDA-approved use (Vyleesi)

The approved use is straightforward: 1.75 mg subcutaneous injection, self-administered via prefilled autoinjector in the abdomen or thigh, at least 45 minutes before anticipated sexual activity. No more than one dose per 24 hours, no more than 8 doses per month.^[14]

The autoinjector is similar in design to an EpiPen — a spring-loaded device that delivers a fixed dose with a button press. No reconstitution required.

Off-label and compounded use

In the peptide community, PT-141 is also widely used by men for erectile dysfunction and by women outside of the strict HSDD indication. These uses are off-label and not supported by Phase 3 evidence:

• Men for ED: Not FDA-approved for this use. Phase 1/2 data is positive but limited. A Phase 2 combination trial with PDE5 inhibitors is underway.
• Compounded formulations: PT-141 is available through compounding pharmacies, typically as lyophilized powder requiring reconstitution. Compounded versions are not bioequivalent to the FDA-approved product.

Comparison with flibanserin (Addyi)

Both drugs are FDA-approved for HSDD, but they're very different in practice:

Neither drug is considered transformative. Both have modest effect sizes and have underperformed commercially.

---

Legal & regulatory status

As of March 2026:

FDA status

PT-141 (bremelanotide) is FDA-approved as Vyleesi for the treatment of acquired, generalized HSDD in premenopausal women. NDA 210557, approved June 21, 2019.^[14]

Key prescribing details:

• No black box warning
• No REMS (Risk Evaluation and Mitigation Strategy) required
• Dispensed through specialty pharmacy (BlinkRx)
• Retail price: approximately $1,160 per 4 autoinjectors
• Patent protection through 2041 (5 Orange Book listed patents)

The product is currently marketed by Cosette Pharmaceuticals, which acquired Vyleesi from Palatin Technologies in January 2024.

WADA / anti-doping status

Bremelanotide is not explicitly listed on the WADA Prohibited List. As an FDA-approved drug, it does not fall under Section S0 (Non-Approved Substances). Athletes should verify via GlobalDRO or their national anti-doping organization.

Note: Melanotan II (the parent compound from which PT-141 is derived) is prohibited under WADA Section S0 as it has no regulatory approval anywhere.

International status

Vyleesi is approved only in the United States. No marketing authorization has been granted in the EU, UK, Australia, Canada, or any other country. A Phase 3 bridging study (NCT04943068) was completed, potentially for Asian-market filings.

---

How PT-141 compares

To put PT-141's evidence base in context with another FDA-approved peptide and a commonly discussed research compound:

The contrast illustrates what FDA approval actually requires. PT-141 went through two large Phase 3 RCTs with over 1,200 participants, a dose-ranging study, dedicated safety analyses, and years of regulatory review. BPC-157 has been studied for over 30 years but has only 3 small human studies totaling about 30 participants.

This doesn't mean PT-141 is "better" — it's a different compound for a different purpose. But it shows why the evidence standard matters: patients making real health decisions deserve to know where the evidence is strong and where it's not.

---

Related content

Peptide

Semaglutide

Another FDA-approved peptide drug. Palatin Technologies is pursuing bremelanotide in combination with tirzepatide for obesity.

Guide

How to Reconstitute Peptides

Essential guide for preparing lyophilized peptides, relevant for compounded PT-141.

News

Kennedy Peptide Reclassification

How reclassification could affect access to PT-141 through compounding pharmacies.

Tool

Reconstitution Calculator

Calculate exact syringe units for PT-141 preparation.

---

References

1. [1]

   Kingsberg SA, Clayton AH, Portman D, et al.. “Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.” Obstet Gynecol. 2019. 134(5):899-908 DOI PubMedRCT

   Two identical Phase 3 RCTs (RECONNECT 301 & 302). Double-blind, placebo-controlled. n=1,247 safety population. Gold-standard design.

2. [2]

   Simon JA, Kingsberg SA, Portman D, et al.. “Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder.” Obstet Gynecol. 2019. 134(5):909-917 DOI PubMedRCT

   52-week open-label extension of RECONNECT. Unblinded. Provides most important long-term data.

3. [3]

   Clayton AH, Althof SE, Kingsberg S, DeRogatis LR, Kroll R, Goldstein I, Kaminetsky J, Spana C, Lucas J, Jordan R, Portman DJ. “Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial.” Womens Health (Lond). 2016. 12(3):325-37 DOI PubMedRCT

   Phase 2b dose-ranging. n=327. Established 1.75 mg as optimal dose for Phase 3.

4. [4]

   Diamond LE, Earle DC, Heiman JR, Rosen RC, Perelman MA, Harning R. “An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist.” J Sex Med. 2006. 3(4):628-638 PubMedPilot study

   First evidence in women. n=18. Double-blind, placebo-controlled. Intranasal route (later abandoned).

5. [5]

   Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. “Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction.” Int J Impot Res. 2004. 16(1):51-59 PubMedPilot study

   Phase 1/2. Small proof-of-concept. Intranasal route. Earliest clinical evidence for male sexual dysfunction.

6. [6]

   Diamond LE, Earle DC, Garcia WD, et al.. “Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response.” Urology. 2005. 65(4):755-759 PubMedPilot study

   Three-way crossover, double-blind. n=19. Proof-of-concept for combination therapy.

7. [7]

   Clayton AH, Kingsberg SA, Portman D, et al.. “Safety Profile of Bremelanotide Across the Clinical Development Program.” J Womens Health. 2022. PubMedSafety study

   Integrated safety review across 43 completed studies. ~3,500 subjects. Most comprehensive safety reference.

8. [8]

   White WB, Myers MG, Jordan R, Lucas J. “Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide.” J Hypertens. 2017. 35:761-768 PubMedRCT

   RCT, double-blind, placebo-controlled. n=397. Important ABPM safety data.

9. [9]

   Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. “PT-141: a melanocortin agonist for the treatment of sexual dysfunction.” Ann N Y Acad Sci. 2003. 994:96-102 PubMedReview

   Foundational paper establishing PT-141 as MC3R/MC4R agonist with central mechanism distinct from PDE5 inhibitors.

10. [10]

    Pfaus JG, Giuliano F, Gelez H. “Bremelanotide: an overview of preclinical CNS effects on female sexual function.” J Sex Med. 2007. 4(Suppl 4):269-279 PubMedAnimal study

    Key mechanistic paper. Rat models show selective increase in solicitation behaviors (desire) via MC4R activation in the mPOA.

11. [11]

    Pfaus JG, Sadiq A, Spana C, Clayton AH. “The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women.” CNS Spectr. 2022. 27(3):281-289 PubMedReview

    Updated mechanism review. MC4R in mPOA activates presynaptic dopamine release, explaining desire-specific effect.

12. [12]

    Dhillon S, Keam SJ. “Bremelanotide: First Approval.” Drugs. 2019. 79(14):1599-1606 PubMedReview

    Comprehensive drug profile at time of FDA approval.

13. [13]

    Cipriani S, Alfaroli C, Maseroli E, Vignozzi L. “An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder.” Expert Opin Pharmacother. 2023. 24(1):15-21 PubMedReview

    Balanced expert review. Notes that overall clinical benefit appears 'modest' despite statistical significance.

14. [14]

    U.S. Food and Drug Administration. “VYLEESI (bremelanotide injection) — Full Prescribing Information.” 2019. Link

---